Table 4 Outcome data in matched patients with and without prehospital TXA administration
Tranexamic acid group | Control group | p value | |
|---|---|---|---|
ICU LOS (days) median, IQR | 7 (2–18) | 7 (2–18) | .125 |
Hospital LOS (days) median, IQR | 19 (8–32) | 18 (8–31) | .238 |
Thromboembolic event (n, %) | 132 (6.1%) | 100 (4.9%) | .080 |
Sepsis (n, %) | 277 (13.3%) | 249 (12.7%) | .570 |
Multiple organ failure (n, %) | 843 (40.0%) | 870 (42.6%) | .087 |
Time to death (days) median, IQR | 2 (1–8) | 2 (1–6) | .933 |
6-h mortality (n, %) | 155 (6.8%) | 208 (9.1%) | .004 |
12-h mortality (n, %) | 239 (10.5%) | 282 (12.4%) | .045 |
24-h mortality (n, %) | 297 (13.1%) | 333 (14.6%) | .122 |
30-day mortality (n, %) | 510 (22.4%) | 524 (23.0%) | .620 |
In-hospital mortality (n, %) | 531 (23.3%) | 553 (24.3%) | .444 |
Expected mortality rate based on RISC II prognosis (%) | 24.8% | 25.1% | .680 |
Death due to hemorrhage (n, %) | 68 (3.0) | 97 (4.3) | .021 |